Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab, and Cryoablation in Pediatric Solid Tumors
NCT05302921Phase 2Completed
- Sponsor
- Children's National Research Institute
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in solid tumor, sponsored by Children's National Research Institute. Primary endpoints: Objective Response Rate at 12 months and Adverse Events at 12 months. Started Feb 2022; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05302921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302921.